CLINICAL_TRIALS
trial_result
· 2020-04-09
Clinical Trial Update: A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma [NA]
Summary
The clinical trial evaluating PLX3397 (pexidartinib) in patients with unresectable or metastatic KIT-mutated melanoma has completed, with results posted in Apri…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Melanoma | NA | Status: COMPLETED | Results posted: 2020-04-09